New updates have been reported about BiomEdit.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BiomEdit has obtained key U.S. patents protecting its engineered probiotic delivery platform, cementing intellectual property around the technology that underpins its lead product, BE-101, and future pipeline assets. The patents cover genetically modified Lactobacillus reuteri strains, composition of matter, methods of use, and in-host delivery systems for sustained expression of therapeutic biomolecules, including antibodies targeting Clostridium perfringens.
These protections directly support BE-101, a first-of-its-kind probiotic vectored antibody biologic intended to prevent necrotic enteritis in broiler chickens through localized delivery of neutralizing molecules in the gut. BE-101 is advancing through field studies and regulatory review, with BiomEdit targeting USDA Center for Veterinary Biologics conditional licensure in Q3 2026 and commercial readiness in Q4 2026, while the same platform is positioned to enable broader animal health applications and potential future expansion into human health.